Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$31.1M Sell
233,740
-372,252
-61% -$42.1M 0.01% 1242
2026
Q1
$67.5M Sell
605,992
-135,068
-18% -$16M 0.03% 651
2025
Q4
$99.9M Sell
741,060
-358,970
-33% -$39.2M 0.04% 432
2025
Q3
$93.4M Sell
1,100,030
-151,735
-12% -$9.3M 0.04% 480
2025
Q2
$9.58M Buy
1,251,765
+264,351
+27% +$1.72M ﹤0.01% 2303
2025
Q1
$6.17M Buy
987,414
+56,235
+6% +$381K ﹤0.01% 2657
2024
Q4
$6.82M Buy
931,179
+285,542
+44% +$2.63M ﹤0.01% 2524
2024
Q3
$7.44M Buy
645,637
+568,035
+732% +$6.81M ﹤0.01% 2473
2024
Q2
$1.03M Sell
77,602
-60,207
-44% -$861K ﹤0.01% 4093
2024
Q1
$1.97M Buy
137,809
+7,492
+6% +$96.6K ﹤0.01% 3757
2023
Q4
$1.39M Buy
+130,317
New +$1.33M ﹤0.01% 3896

Other funds holding ABVX

Israel Englander's ABVX Position: Q2 2026 in Review

Israel Englander reduced its Abivax (ABVX) stake by 61% in Q2 2026, selling an estimated $42.1M and leaving 233,740 shares worth $31.1M. The position accounts for 0.01% of the portfolio, ranked #1242.

Israel Englander first reported a position in ABVX in Q4 2023 and has held it in 11 quarters since. The position peaked at $99.9M in Q4 2025. 302 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

  • Israel Englander held 233,740 shares of Abivax worth $31.1M as of Q2 2026.
  • Israel Englander sold 372,252 Abivax shares in Q2 2026, an estimated $42.1M.
  • Abivax made up 0.01% of Israel Englander's portfolio in Q2 2026, its #1242 holding.
  • Israel Englander first reported a position in Abivax in Q4 2023 and has held it in 11 quarters since.
  • Israel Englander's Abivax position peaked at $99.9M in Q4 2025.
  • 302 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.